JTT-705 (Japan Tobacco)

Current Opinion in Investigational Drugs

Volumn 5, Issue 3, 2004, Pages 339-343

  Linders, Joannes T M ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTILIPEMIC AGENT; THIOL DERIVATIVE;

ANIMAL; CHEMISTRY; HUMAN; HYPERLIPIDEMIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTILIPEMIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; HYPERLIPIDEMIAS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

EID: 3042573210     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. 377215 A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H Nature 2000 406 6792 203-207
2. 386388 Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino) benzenethiols, and S-(2-(acylamino)phenyl) alkanethioate as novel inhibitors of cholesteryl ester transfer protein. Shinkai H, Maeda K, Yamasaki T, Okamoto H, Uchida I J MED CHEM 2000 43 19 3566-3572
3. 394615 Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: Involvement of a critical cysteine. Hope HR, Heuvelman D, Duffin K, Smith C, Zablocki J, Schilling R, Hegde S, Lee L, Witherbee B, Baganoff M, Bruce C et al J LIPID RES 2000 41 10 1604-1614
4. 421742 The discovery of new cholesteryl ester transfer protein inhibitors. Sikorski JA, Connolly DT CURR OPIN DRUG DISCOVERY DEV 2001 4 5 602-613
5. 422640 Drugs - lipid conference: Opening night observations. SALOMON SMITH BARNEY 2001 September 10
6. 425411 Drugs Affecting Lipid Metabolism - XIVth International Symposium, New York, NY, USA. Calabresi L IDDB MEETING REPORT 2001 September 9-12
7. 426135 The Implications of the structure of bactericidal/permeability- increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Bruce C, Beamer LJ, Tall AR CURR OPIN STRUCT BIOL 1998 8 4 426-434
8. 434133 The efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705. de Grooth GJ, Posma JL, Jonker JJC, Basart DCG, Kastelein JJP INT SYMP ON DRUGS AFFECT LIPID METAB 2001 September 09-12
9. 434139 A cholesterol ester transfer protein (CETP) inhibitor, JTT-705, increases platelet-activating factor acetylhydrolase (PAF-AH) and decreases lysophosphatidylcholine (LPC). Zhang B, Shimoji E, Fan P, Mei JR, Saku K INT SYMP ON DRUGS AFFECT LIPID METAB 2001 September 9-12 56
10. 437091 Clinical development (as of November 15, 2001). Japan Tobacco Inc COMPANY WORLD WIDE WEBSITE 2002 January 23
11. 440308 Cholesteryl ester transfer protein inhibitors. Shinkai H EXP OPIN THER PAT 2001 11 5 739-745
12. 443762 The efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705. de Grooth GK, Kastelein JJP CIRCULATION 2001 104 17 Abs 848
13. 451171 Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low-density lipoprotein in J774 macrophage. Kobayashi J, Okamoto H, Otabe M, Bujo H, Saito Y ATHEROSCLEROSIS 2002 162 1 131-135
14. 469489 Japan Tobacco; pipeline validation. Japan Tobacco Inc COMPANY WORLD WIDE WEBSITE 2002 November 07
15. 471868 Metabolic background modulates the effects of CETP inhibitor on the in vivo kinetics of Apo A-I. Shimoji E, Zhang B, Fan P, Saku K CIRCULATION 2002 106 19 Abs 921
16. 479249 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, de Graaf J, Zwinderman AH, Posma JL, Van Tol A, Kastelein JJP CIRCULATION 2002 105 18 2159-2165
17. 479250 Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H CLIN SCI 2002 103 6 587-594
18. 479252 A cholesterol ester transfer protein inhibitor increased in vivo synthetic rates and liver mRNA levels of apolipoprotein A-I. Shimoji E, Zhang B, Fan P, Saku K J AM COLL CARDIOL 2002 39 5 226A
19. 484149 Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia. Inazu A, Mabuchi H CURR OPIN INVEST DRUGS 2003 4 3 291-297
20. 485395 American Chemical Society - 225th National Meeting (Part XIV), New Orleans, LA, USA. Gomez J IDDB MEETING REPORT 2003 March 23-27
21. 494774 Barnett International Conference - Emerging Cardiovascular Therapeutics (Part I), Cambridge, MA, USA. Zavoico G IDDB MEETING REPORT 2003 June 10-11
22. 495021 Analyst meeting, late stage pipeline update. Pfizer Inc COMPANY PRESENTATION 2003 June 17
23. 502778 Effect of JTT-705 on cholesteryl ester transfer protein and plasma levels in normolipidemic animals. Okamoto H, Iwamoto Y, Maki M, Sotani T, Yonemori F, Wakitani K EUR J PHARMACOL 2003 466 1-2 147-154
24. 504409 Increased high-density lipoprotein levels caused by a common cholesteryl ester transfer protein gene mutation. Inazu A, Brown ML, Hedsler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR N ENGL J MED 1990 323 18 1234-1238
25. 504410 Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR J CLIN INVEST 1996 97 12 2917-2923
26. 504568 High density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport. Von Eckardstein A, Nofer JR, Assmann G ARTERIOSCLER THROMB VASC BIOL 2001 21 1 13-27
27. 504569 Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M J CLIN INVEST 1995 96 6 2882-2891
28. 504573 Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB J AM MED ASSOC 1986 256 20 2835-2838
29. 504588 Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P et al J AM MED ASSOC 1988 260 5 641-651
30. 504589 Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report. Gotto AM Jr CIRCULATION 2001 103 17 2213-2218
31. 504590 Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Rackley CE CLIN CARDIOL 1996 19 9 683-689
32. 504591 Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA ARTERIOSCLER THROMB VASC BIOL 1998 18 7 1046-1053
33. 504605 Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Barter PJ, Hopkins GJ, Calvert GD BIOCHEM J 1982 208 1 1-7
34. 504606 Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR ARTERIOSCLER THROMB VASC BIOL 1999 19 4 1105-1110
35. 504607 Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW NATURE 1993 364 6432 73-75
36. 504608 Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A J BIOL CHEM 1998 273 9 5033-5036
37. 504610 Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD et al ARTERIOSCLER THROMB VASC BIOL 2000 20 9 2106-2112
38. 504611 Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR J CLIN INVEST 1995 96 4 2071-2074
39. 504613 Lipoprotein lipase deficiency and CETP in streptozotocin- treated apoB-expressing mice. Kako Y, Masse M, Huang LS, Tall AR, Goldberg IJ J LIPID RES 2002 43 6 872-877
40. 504614 High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen B, Hoyt RF Jr, Marcovina S, Brewer HB Jr, Santamarina-Fojo S NAT MED 1997 3 7 744-749
41. 504650 HDL cholesterol predicts coronary heart disease mortality in older persons. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, Berkman LF, Seeman TE, Glynn RJ, Hennekens CH et al J AM MED ASSOC 1995 274 7 539-544
42. 504652 Regulation of cholesteryl ester transfer protein (CETP) activity: Review of in vitro and in vivo studies. Lagrost L BIOCHIM BIOPHYS ACTA 1994 1215 3 209-236
43. 504683 Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR ARTERIOSCLER THROMB VASC BIOL 2003 23 2 160-167
44. 509581 Discovery and development of JTT-705, a potent cholesteryl ester transfer protein (CETP) inhibitor. Maeda K, Okamoto H, Uchida I, Haruta J, Shinkai H AFMC INT MED CHEM SYMP 2003 5 A117